FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563485831> ?p ?o ?g. }

• W2563485831 abstract "Abstract Introduction: Older age, poor performance status, diminished organ function and adverse genetic features are poor prognostic factors in treatment of ALL. Our goal is to develop prognostic models predicting complete response (CR), death in CR, 2-month mortality and survival in adult pts with ALL, which would be used to assist pts and oncologists to establish expectations with intensive chemotherapy. Methods: A total of 434 pts with ALL treated with intensive chemotherapy between 2000 and 2015 were analyzed. Frontline treatments included hyperCVAD alone (n=152) or in combination with rituximab (n=156) [Thomas D, et.al, JCO 2010], or ofatumumab (n=34), and Augmented-BFM (n=92) [Rytting ME, et al Cancer 2014]. Following clinical features were analyzed; age, gender, diagnosis (B or T-ALL), performance status (Zubrod), prior malignancy, prior chemotherapy, white blood cell count, platelet count, hemoglobin level, peripheral blood (PB) blast, bone marrow (BM) blast, mixed lineage leukemia (MLL) gene rearrangements, albumin level, total bilirubin level, estimated glomerular filtration rate (GFR by the Modification of Diet in Renal Disease Study equation) and chemotherapy type. Univariate and multivariate analyses of clinical features associated with CR, death in CR, 2-month mortality and survival were performed. Results: Pts characteristics are summarized in Table 1. The overall CR rate, death in CR rate, 2-month mortality rate, 1-year and 5-year survival rates were 94%, 15%, 8%, 80%, and 47%, respectively. In multivariate analysis, we identified prognostic factors associated with CR, death in CR, 2-month mortality, and survival (Table 2). Age > 40 years, performance status ≥ 2, total bilirubin >1 mg/dL, GFR < 60 mL/min/1.73m2, albumin < 3.5 g/dL, WBC > 50 x109/L and presence of MLL gene rearrangements were identified as independent adverse prognostic features for overall survival (OS). Because all predictive features identified had similar statistical impact, patients were divided into four different risk categories: 1) low (no adverse feature) 92 pts (21%), 2) intermediate-1 (1 adverse feature) 138 pts (32%), 3) intermediate-2 (2 adverse features) 111 pts (26%), and 4) high (≥ 3 adverse features) 93 pts (21%). Median OS survival was not reached in low and intermediate-1 categories, and it was 40 and 15 months for intermediate-2 and high risk categories respectively (p<0.001). The 5-year survival rates were 65%, 57%, 42%, and 22%, respectively (Figure 1). Conclusion: Prognostic model predicting survival in adult ALL pts were developed based on standard readily available baseline clinical features, which may assist in therapeutic and investigational decisions. This prognostic model is based on retrospective analysis, and further validation is needed in independent study groups. Table 1. Characteristics of the Study Group (n=434) Parameter Category No. (%) Age > 40 years old yes 207 (48) no 227 (52) Sex female 198 (46) male 236 (54) Diagnosis Pre-B 419 (97) Pre-T 15 (3) Prior Malignancy yes 46 (11) no 388 (89) Prior Chemotherapy yes 31 (7) no 403 (93) Prior Radiotherapy yes 21 (5) no 413 (95) Performance Status ≥ 2 yes 69 (16) no 365 (84) MLL Gene Rearrangement yes 34 (8) no 400 (92) WBC, x109/L ≤ 50 389 (90) > 50 45 (10) Platelet, x109/L < 100 93 (21) ≥ 100 341 (79) Hg, gr/dl < 8 144 (33) ≥ 8 290 (67) PB Blast yes 337 (78) no 97 (22) BM Blast, % ≥ 50 388 (89) <50 46 (11) Albumin, gr/dl < 3.5 213 (49) ≥ 3.5 221 (51) Total Bilirubin, mg/dl > 1 53 (12) ≤ 1 381 (88) GFR, ml/min/1.73m2 < 60 45 (10) ≥ 60 389 (90) Chemotherapy HCVAD 152 (35) HCVAD + Rituximab 156 (36) HCVAD + Ofatumumab 34 (8) AUG-BFM 92 (21) Table 2. Multivariate Analysis of Adverse Factors Associated with the Clinical Outcomes Outcome Factor p O.R. C.I. Death in CR Age > 40 years old 0.004 3.0 1.4-6.3 2-Month Mortality Total Bilirubin > 1 mg/dl 0.018 3.0 1.2-6.0 Albumin < 3.5 gr/dl 0.023 2.6 1.1-6.0 GFR < 60 ml/min/1.73m2 0.009 3.2 1.3-7.6 Complete Response GFR < 60 ml/min/1.73m2 0.001 0.2 0.1-0.5 Overall Survival Age > 40 years old 0.002 0.6 0.5-0.8 Performance Status ≥ 2 <0.001 0.5 0.4-0.7 Total Bilirubin > 1 mg/dl 0.029 0.7 0.4-0.9 GFR < 60 ml/min/1.73m2 0.003 0.6 0.4-0.8 Albumin < 3.5 gr/dl 0.045 0.8 0.6-0.9 WBC > 50 x109/L 0.030 0.6 0.4-0.9 MLL Gene Rearrangement 0.032 0.6 0.4-0.9 Figure 1. Overall Survival by Risk Categories Figure 1. Overall Survival by Risk Categories Disclosures Konopleva: Novartis: Research Funding; AbbVie: Research Funding; Stemline: Research Funding; Calithera: Research Funding; Threshold: Research Funding." @default.
• W2563485831 created "2017-01-06" @default.
• W2563485831 creator A5000750846 @default.
• W2563485831 creator A5013173470 @default.
• W2563485831 creator A5014154182 @default.
• W2563485831 creator A5015101485 @default.
• W2563485831 creator A5021380291 @default.
• W2563485831 creator A5022647201 @default.
• W2563485831 creator A5029750735 @default.
• W2563485831 creator A5049385583 @default.
• W2563485831 creator A5050041791 @default.
• W2563485831 creator A5051949215 @default.
• W2563485831 creator A5061026876 @default.
• W2563485831 creator A5071687115 @default.
• W2563485831 creator A5084290698 @default.
• W2563485831 creator A5085521139 @default.
• W2563485831 creator A5089428686 @default.
• W2563485831 creator A5090435894 @default.
• W2563485831 date "2015-12-03" @default.
• W2563485831 modified "2023-10-15" @default.
• W2563485831 title "Results of Intensive Chemotherapy in 434 Adult Patients (pts) with Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL): Predictive Prognostic Model for Survival" @default.
• W2563485831 doi "https://doi.org/10.1182/blood.v126.23.3722.3722" @default.
• W2563485831 hasPublicationYear "2015" @default.
• W2563485831 type Work @default.
• W2563485831 sameAs 2563485831 @default.
• W2563485831 citedByCount "0" @default.
• W2563485831 crossrefType "journal-article" @default.
• W2563485831 hasAuthorship W2563485831A5000750846 @default.
• W2563485831 hasAuthorship W2563485831A5013173470 @default.
• W2563485831 hasAuthorship W2563485831A5014154182 @default.
• W2563485831 hasAuthorship W2563485831A5015101485 @default.
• W2563485831 hasAuthorship W2563485831A5021380291 @default.
• W2563485831 hasAuthorship W2563485831A5022647201 @default.
• W2563485831 hasAuthorship W2563485831A5029750735 @default.
• W2563485831 hasAuthorship W2563485831A5049385583 @default.
• W2563485831 hasAuthorship W2563485831A5050041791 @default.
• W2563485831 hasAuthorship W2563485831A5051949215 @default.
• W2563485831 hasAuthorship W2563485831A5061026876 @default.
• W2563485831 hasAuthorship W2563485831A5071687115 @default.
• W2563485831 hasAuthorship W2563485831A5084290698 @default.
• W2563485831 hasAuthorship W2563485831A5085521139 @default.
• W2563485831 hasAuthorship W2563485831A5089428686 @default.
• W2563485831 hasAuthorship W2563485831A5090435894 @default.
• W2563485831 hasConcept C126322002 @default.
• W2563485831 hasConcept C141071460 @default.
• W2563485831 hasConcept C143998085 @default.
• W2563485831 hasConcept C144301174 @default.
• W2563485831 hasConcept C159641895 @default.
• W2563485831 hasConcept C179755657 @default.
• W2563485831 hasConcept C2776694085 @default.
• W2563485831 hasConcept C2776907518 @default.
• W2563485831 hasConcept C2778336483 @default.
• W2563485831 hasConcept C38180746 @default.
• W2563485831 hasConcept C71924100 @default.
• W2563485831 hasConcept C90924648 @default.
• W2563485831 hasConceptScore W2563485831C126322002 @default.
• W2563485831 hasConceptScore W2563485831C141071460 @default.
• W2563485831 hasConceptScore W2563485831C143998085 @default.
• W2563485831 hasConceptScore W2563485831C144301174 @default.
• W2563485831 hasConceptScore W2563485831C159641895 @default.
• W2563485831 hasConceptScore W2563485831C179755657 @default.
• W2563485831 hasConceptScore W2563485831C2776694085 @default.
• W2563485831 hasConceptScore W2563485831C2776907518 @default.
• W2563485831 hasConceptScore W2563485831C2778336483 @default.
• W2563485831 hasConceptScore W2563485831C38180746 @default.
• W2563485831 hasConceptScore W2563485831C71924100 @default.
• W2563485831 hasConceptScore W2563485831C90924648 @default.
• W2563485831 hasLocation W25634858311 @default.
• W2563485831 hasOpenAccess W2563485831 @default.
• W2563485831 hasPrimaryLocation W25634858311 @default.
• W2563485831 isParatext "false" @default.
• W2563485831 isRetracted "false" @default.
• W2563485831 magId "2563485831" @default.
• W2563485831 workType "article" @default.